A guide to Australia's big experiment with biosimilars


Until the 21st century, rheumatoid arthritis (RA) was considered a  hopeless diagnosis for many patients. Over  the past two decades, however, rheumatology has been catapulted to the cutting edge of research into immune-modulating therapies and an increasing number of biological and synthetic disease-modifying antirheumatic drugs (DMARDs) are emerging.

For a significant number of patients with RA battling pain and disability with only methotrexate, steroids and NSAIDS, the introduction of biological therapies has been transformative.

Since PBAC approval of